Welcome to our dedicated page for EUDA Health Holdings news (Ticker: EUDA), a resource for investors and traders seeking the latest updates and insights on EUDA Health Holdings stock.
EUDA Health Holdings Limited (NASDAQ: EUDA) is a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China. Company news highlights its strategy in preventive health, longevity-focused care, regenerative medicine and wellness consumer products, alongside a Singapore-based property management business.
News updates for EUDA often cover developments in its longevity and stem cell platforms, such as agreements with Shenzhen Inno Immune Co., Ltd., the launch of a nationwide stem cell extraction, cryostorage and clinical delivery platform in China, and the establishment of a longevity clinic in Shenzhen. Releases also describe EUDA’s partnerships with institutions like Wuhan Kaien Hospital and CK Health Plus’ expansion into India through SafeRock India.
Investors and observers can follow announcements about EUDA Helixé 2.0, a premium vitality and longevity supplement with upgraded formulation and delivery technology, as well as disclosures on the integration of the QB utility token into EUDA’s digital health and rewards platform. These items illustrate how the company combines wellness products, regenerative medicine programs and digital assets within one ecosystem.
EUDA’s news flow also includes capital markets activities and governance updates, such as securities purchase agreements, warrant amendments, convertible note arrangements and changes to its board of directors, as reported in press releases and related Form 6-K filings. The EUDA news page on Stock Titan aggregates these developments so readers can review corporate actions, strategic partnerships, product launches and financing events linked to EUDA’s non-invasive healthcare and longevity strategy.
EUDA Health (NASDAQ: EUDA) announced a second amendment to its Streeterville warrant agreement dated January 13, 2026. The amendment reduces the warrant exercise price from US$4.00 to US$2.00 and lowers the forced-exercise minimum closing price from US$6.00 to US$3.00. All other warrant terms remain unchanged. Management described the change as a technical adjustment to align terms with current market conditions while preserving capital-structure flexibility and maintaining the company’s strategic focus on preventive health, longevity, and personalised healthcare.
EUDA (NASDAQ: EUDA) said its subsidiary EUDA Health entered a convertible loan agreement with Shenzhen Inno on Jan 13, 2026 to fund a cGMP facility upgrade in Shenzhen. EUDA expects to invest up to RMB 6 million in two tranches (RMB 1 million initial; RMB 5 million conditional), subject to due diligence, regulatory approvals and definitive documentation. The note carries an expected 6% per annum interest, payable semi-annually, and is convertible into equity or redeemable with accrued interest if not converted.
The deal is intended to anchor EUDA’s China regenerative medicine platform and support future expansion.
EUDA Health Holdings (NASDAQ: EUDA) announced an amendment to its warrant agreement with Streeterville Capital dated December 4, 2025. The amendment reduces the Warrant exercise price from $6.00 to $4.00 and lowers the minimum closing price that triggers a Forced Exercise from $7.50 to $6.00. The original Warrant was issued for an aggregate purchase price of $100,000 and is exercisable into up to 2,000,000 ordinary shares. The Cash Exercise Period is ninety (90) days from issuance, after which Streeterville will be deemed to have made a cashless exercise at a 1-for-10 conversion if not exercised for cash.
EUDA (NASDAQ: EUDA) announced on December 30, 2025 the launch of a nationwide stem cell extraction, cryostorage and clinical delivery platform in China in partnership with Shenzhen Inno Immune and Wuhan Kaien Hospital. The platform combines centralized processing with decentralized clinical access, cold-chain logistics and integration into longevity medicine.
Key infrastructure includes an initial ~50,000 patient-unit cryogenic hub in Shenzhen and a planned ~200,000 patient-unit capacity at Wuhan Kaien, plus a partner network of extraction clinics and regulated transport for sample movement and clinical delivery.
EUDA Health (NASDAQ: EUDA) will launch EUDA Helixé 2.0 in January 2026 as an upgraded premium vitality and longevity supplement.
Key changes include a 20% increase in New Zealand deer placenta powder (from 100 mg to 120 mg), replacement of L-glutathione with D-alpha-tocopherol (Vitamin E, 1.4 mg equivalent), advanced preservation and delivery methods (freeze drying, refining, nitrogen encapsulation, and nano emulsification replacing enteric coating), a new proprietary bottle design, and New Zealand Halal certification to enable broader Muslim-market distribution.
EUDA (NASDAQ: EUDA) launched a comprehensive stem cell therapy platform and opened its first longevity clinic in Shenzhen on Dec 23, 2025, accelerating its regenerative-medicine strategy.
The company is upgrading Shenzhen Inno’s cGMP facility into a production and innovation center integrating GO POSB’s iPSC platform and technologies from two Japanese partners to support iPSC expansion, stem cell preparation and T-cell immunotherapies. EUDA also holds distribution rights for Shenzhen Inno’s T-cell immunotherapies and stated an intention to acquire GO POSB. The Shenzhen clinic will offer advanced cell therapies, AI-guided life-cycle management, and integrated Eastern/Western/functional medicine.
EUDA Health Holdings (NASDAQ: EUDA) announced on December 22, 2025 a technology integration that adds the QB utility token into its digital health and rewards platform.
Customers and agents can earn and redeem QB tokens for EUDA offerings including Bioenergy Capsule treatments, Euda Helixe supplements, and selected stem cell services. EUDA will receive QB tokens solely in exchange for products and services, recorded as non-monetary, product-based transactions.
The QB token is built on Binance Smart Chain and interoperates with the USD1 stablecoin (1:1 redeemable for US dollar) using Chainlink CCIP; QB Limited is the token issuer and exclusive distributor of Euda Helixe in Hong Kong and Macau.
EUDA Health Holdings (NASDAQ: EUDA) announced plans to integrate a third‑party utility cryptocurrency called QB into its digital health and rewards platform, with QB scheduled for launch in January 2026. The token will be usable across EUDA’s ecosystem for payments, rewards, and access to healthcare products and partner services in Singapore, Malaysia, and China. EUDA also plans to hold QB in its digital asset treasury to support long‑term financial flexibility and participation in blockchain initiatives. The initiative aims to link healthcare engagement with decentralized finance to enhance loyalty, access, and community participation.
EUDA Health Holdings (NASDAQ: EUDA) announced it entered a securities purchase agreement dated November 26, 2025 to sell a convertible warrant to Streeterville Capital for an aggregate purchase price of US$100,000. The Warrant is exercisable into up to 2,000,000 newly issued ordinary shares at an exercise price of US$6.00 per share and was offered under the company’s Form F-3 shelf registration (File No. 333-282723) with a related prospectus supplement.
The Warrant allows cash-only exercise for 90 days from issuance (subject to extension). The company may require partial forced exercise up to 10% of cumulative dollar trading volume if the share price is ≥ US$7.50 for five consecutive trading days and trading volume in that period is at least US$1,500,000. Management described the financing as flexibility to support expansion across Singapore, Malaysia and China.
EUDA (NASDAQ: EUDA) announced on October 23, 2025 that its wholly owned subsidiary CK Health Plus will expand into India via a master license and representative partnership with SafeRock India.
The agreement aims to deploy CK Health Plus’ Bioenergy Capsule Therapies and EUDA Helixé supplements across major Indian cities including Mumbai and Bangalore, leveraging SafeRock India’s systems integration capabilities and nationwide network to roll out a network-marketing wellness ecosystem.